季節性流感疫苗

季節性流感疫苗
	美国海军人员接种疫苗
臨床資料
商品名（英语：Drug nomenclature）	Fluarix、Fluzone、others
AHFS/Drugs.com	Monograph
给药途径	IM、鼻内
ATC碼	J07BB01 (WHO) ;
法律規範狀態
法律規範	美：处方药（℞-only）;
识别信息
CAS号	1704512-59-3

季節性流感疫苗，簡稱流感疫苗（influenza vaccine，flu shot），為針對流行性感冒（季节性流感）的疫苗。因為流感病毒變化的速度很快，一年會發展新的流感疫苗兩次。大部分狀況下，疫苗有中度到高度的保護力；然而每年情況略有不同。^[2]^[3]對65歲以上的長者，目前證據較缺乏。^[4]^[5]平均來說，他們可以減少半日因病而上班必須請假的狀況。^[6]有打疫苗的孩童，可以保護他們周遭的人。^[2]

事实速览 臨床資料, 商品名（英语：Drug nomenclature） ...

关闭

世界衛生組織和美國疾病控制與預防中心都建議幾乎任何大於六個月的人，每年應該施打流感疫苗。^[2]^[7]尤其是孕婦、六個月大至五歲的孩童、有慢性疾病者、美洲原住民、以及醫療相關人員。^[2]^[1]

分類

流感疫苗多分为：（裂解）灭活疫苗（IIV）及裂解亚单位疫苗^[8]、减毒活疫苗（LAIV）、重组亚单位疫苗（RIV）^[9]。灭活疫苗（含灭活全病毒、灭活裂解、裂解亚单位三个子类^[8]）最为常用，又分为三价与四价剂型。

其中，对于流感的灭活疫苗是用灭活剂来处理在鸡蛋或细胞培养物中制备的野生型病毒。如果季节性疫苗所包含的病毒在抗原上与最终流行的病毒非常匹配，灭活疫苗通常可以预防一半以上的严重流感相关的疾病^[10]。然而，这些人群应禁止接种该疫苗^[10]

接种流感疫苗后出现过危及生命的过敏反应
对疫苗中的任何成分（其中一些含有少量鸡蛋蛋白）严重过敏的人
有格林-巴利综合征病史的人

疫苗通常每年接种一剂，但 6 个月至 8 岁的儿童在一个流感季节可能需要接种两剂。

第二种主要流感疫苗是通过鼻腔喷雾局部注射的三价或四价减毒活疫苗。每年都会制备新的疫苗，以解决抗原漂移问题^[10]。该疫苗在美国许可用于 2 至 49 岁的人群^[10]。

有效性

过去灭活疫苗及减毒疫苗曾产生抗体依赖增强作用使2009年接种季节性甲型H1N1（针对类似A/Brisbane/59/2007的一株）疫苗的人更容易得甲型H1N1pdm09（A/California/7/2009病毒）新型流感。^[11]2010年起H1N1株被改为“pandemic系”，2022年为人6B.1a.5a.2系。^[12]2011年起开始推广亚单位疫苗。

年度更新

在每年的季节性流行期间，编码血凝素和神经氨酸酶蛋白的基因都会发生点突变，而这两种蛋白是保护性抗体的主要靶标。流行性流感病毒株的这种抗原漂移导致监管官员和生产商每年都要调整流感疫苗中的病毒抗原。偶尔，人类和禽类共同感染的情况下，分割的病毒基因组会重新出现，产生一种新的病毒，也就是抗原转变，从而导致大流行。1918 年（H1N1）、1957 年（H2N2）、1968 年（H3N2）和 2009 年（新型 H1N1）都发生过全球性的大流行。在这种情况下，必须对疫苗进行重大调整^[10]。

以下为北半球每年流感疫苗针对的毒株列表。Starting in the 2012–2013 season, the recommendation shifted from a trivalent influenza vaccine (TIV) containing three strains to a quadrivalent influenza vaccine (QIV) that contains both influenza B lineages.^{[來源請求]}

更多信息 年度, H1N1甲流 ...

年度	H1N1甲流	演化支	类似猪H1支^{[note 1]}	H3N2甲流	演化支	乙流Victoria株	演化支	乙流山形株
November 1998–April 1999^[13]	A/Beijing/262/95 (H1N1)-like virus	未谱系		A/Sydney/5/97 (H3N2)-like virus		N/A		B/Beijing/184/93-like virus
November 1999–April 2000^[14]	A/Beijing/262/95 (H1N1)-like virus			A/Sydney/5/97 (H3N2)-like virus		B/Shangdong/7/97-like virus^{[note 2]}		B/Beijing/184/93-like virus^{[note 2]}
2000–2001^[15]	A/New Caledonia/20/99 (H1N1)-like virus			A/Moscow/10/99 (H3N2)-like virus		N/A		B/Beijing/184/93-like virus
2001–2002^[16]						N/A		B/Sichuan/379/99-like virus
2002–2003^[17]						B/Hong Kong/330/2001-like virus		N/A
2003–2004^[18]						B/Hong Kong/330/2001-like virus		N/A
2004–2005^[19]				A/Fujian/411/2002 (H3N2)-like virus		N/A		B/Shanghai/361/2002-like virus
2005–2006^[20]				A/California/7/2004 (H3N2)-like virus		N/A		B/Shanghai/361/2002-like virus
2006–2007^[21]				A/Wisconsin/67/2005 (H3N2)-like virus		B/Malaysia/2506/2004-like virus		N/A
2007–2008^[22]	A/Solomon Islands/3/2006 (H1N1)-like virus			A/Wisconsin/67/2005 (H3N2)-like virus		B/Malaysia/2506/2004-like virus		N/A
2008–2009^[23]	A/Brisbane/59/2007 (H1N1)-like virus		1B.2.1^[12]	A/Brisbane/10/2007 (H3N2)-like virus		N/A		B/Florida/4/2006-like virus
2009–2010^[24]	A/Brisbane/59/2007 (H1N1)-like virus		1B.2.1^[12]	A/Brisbane/10/2007 (H3N2)-like virus		B/Brisbane/60/2008-like virus		N/A
2010–2011^[25]	A/California/7/2009 (H1N1)-like virus	(0)^[26]	1A.3.3.2^[12]	A/Perth/16/2009 (H3N2)-like virus				N/A
2011–2012^[27]	A/California/7/2009 (H1N1)-like virus			A/Perth/16/2009 (H3N2)-like virus				N/A
2012–2013^[28]	A/California/7/2009 (H1N1)pdm09^{[note 3]}-like virus^[29]			A/Victoria/361/2011 (H3N2)-like virus				B/Wisconsin/1/2010-like virus
2013–2014^[30]	A/California/7/2009 (H1N1)pdm09^{[note 3]}-like virus			A(H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011^{[note 4]}				B/Massachusetts/2/2012-like virus
2014–2015^[31]	A/California/7/2009 (H1N1)pdm09^{[note 3]}-like virus			A/Texas/50/2012 (H3N2)-like virus^{[note 5]}				B/Massachusetts/2/2012-like virus
2015–2016^[32]	A/California/7/2009 (H1N1)pdm09^{[note 3]}-like virus			A/Switzerland/9715293/2013 (H3N2)-like virus				B/Phuket/3073/2013-like virus
2016–2017^[33]^[34]	A/California/7/2009 (H1N1)pdm09^{[note 3]}-like virus			A/Hong Kong/4801/2014 (H3N2)-like virus	3C.2a
2017–2018^[35]^[36]	A/Michigan/45/2015 (H1N1)pdm09^{[note 3]}-like virus^[37]	6B.1	不再使用	A/Hong Kong/4801/2014 (H3N2)-like virus	3C.2a
2018–2019^[38]^[39]	A/Michigan/45/2015 (H1N1)pdm09^{[note 3]}-like virus	6B.1		A/Singapore/INFIMH-16-0019/2016 (H3N2)-like virus	3C.2a1	B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)
2019–2020^[40]^[41]^[42]	A/Brisbane/02/2018 (H1N1)pdm09^{[note 3]}-like virus	6B.1A.1		A/Kansas/14/2017 (H3N2)-like virus	3C.3a	B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage)
2020–2021 egg-based vaccines^[43]	A/Guangdong-Maonan/SWL1536/2019 (H1N1)pdm09-like virus^{[note 3]}	6B.1A.5a.1		A/Hong Kong/2671/2019 (H3N2)-like virus	3C.2a1b.1b	B/Washington/02/2019 (B/Victoria lineage)-like virus	V1A.3
2020–2021 cell- or recombinant-based vaccines^[43]	A/Hawaii/70/2019 (H1N1)pdm09-like virus^{[note 3]}	6B.1A.5a.1		A/Hong Kong/45/2019 (H3N2)-like virus	3C.2a1b.1b
2021–2022 egg-based vaccines^[44]	A/Victoria/2570/2019 (H1N1)pdm09-like virus^{[note 3]}	6B.1A.5a.2		A/Cambodia/e0826360/2020 (H3N2)-like virus	3C.2a1b.2a.1
2021–2022 cell- or recombinant-based vaccines^[44]	A/Wisconsin/588/2019 (H1N1)pdm09-like virus^{[note 3]}			A/Cambodia/e0826360/2020 (H3N2)-like virus	3C.2a1b.2a.1
2022–2023 egg-based vaccines^[45]	A/Victoria/2570/2019 (H1N1)pdm09-like virus			A/Darwin/9/2021 (H3N2)-like virus	3C.2a1b.2a.2a	B/Austria/1359417/2021 (B/Victoria lineage)-like virus	V1A.3a.2
2022–2023 cell- or recombinant-based vaccines^[45]	A/Wisconsin/588/2019 (H1N1)pdm09-like virus			A/Darwin/6/2021 (H3N2)-like virus
2023–2024 egg-based vaccines^[46]	A/Victoria/4897/2022 (H1N1)pdm09-like virus	6B.1A.5a.2a.1		A/Darwin/9/2021 (H3N2)-like virus
2023–2024 cell- or recombinant-based vaccines^[46]	A/Wisconsin/67/2022 (H1N1)pdm09-like virus	6B.1A.5a.2a.1		A/Darwin/6/2021 (H3N2)-like virus

关闭

[N 1]
早期针对人类流感病毒进行详细谱系，仅存在最接近的猪H1流感病毒的HA蛋白谱系，一些最接近人H1N1流感病毒的猪H1流感病毒甚至属于H1N2型。
[N 2]
The recommendation was for either the B Victoria or the B Yamagata strain.
[N 3]
(H1N1)pdm09 is newer nomenclature for the 2009 pandemic H1N1 virus, not a different strain.
[N 4]
It is recommended that A/Texas/50/2012 is used as the A(H3N2) vaccine component because of antigenic changes in earlier A/Victoria/361/2011-like vaccine viruses (such as IVR-165) resulting from adaptation to propagation in eggs.
[N 5]
A/Texas/50/2012 is an A(H3N2) virus that following adaptation to growth in eggs has maintained antigenic properties similar to the majority of recently circulating cell-propagated A(H3N2) viruses including A/Victoria/361/2011

副作用

疫苗大致上是安全的。在兒童，有5-10%會有發燒的反應，也有可能有肌肉痛、疲倦等症狀。在某些年份，疫苗可能在年長者引起格林－巴利综合征，機率約百萬分之一。疫苗不應該施打於對蛋嚴重過敏者、或有流感疫苗過敏史者。疫苗有不活化疫苗及減毒疫苗兩種。孕婦應該使用不活化疫苗。在施打類型方面，有肌肉內注射、鼻噴劑、皮內注射等形式。^[2]

歷史

對抗流感的疫苗在1930年代開始，一直到1945年開始在美國廣為使用。^[47]^[48]它被列在世界衛生組織基本藥物標準清單，即其建議之對基礎健康照護系統最重要的藥物。^[49]在2014年，其批發價約5.25美元。^[50]在美國，則是少於25美元。^[51]

參考

[1]
Influenza Virus Vaccine Inactivated. The American Society of Health-System Pharmacists. [2015-01-08]. （原始内容存档于2014-12-25）.
[2]
Vaccines against influenza WHO position paper – November 2012. Releve Epidemiologique Hebdomadaire. 2012-11-23, 87 (47) [2022-11-02]. ISSN 0049-8114. PMID 23210147. （原始内容存档于2022-11-02）.
[3]
Manzoli, Lamberto; Ioannidis, John P.A.; Flacco, Maria Elena; De Vito, Corrado; Villari, Paolo. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses. Human Vaccines & Immunotherapeutics. 2012-07, 8 (7) [2022-11-02]. ISSN 2164-5515. PMC 3495721 . PMID 22777099. doi:10.4161/hv.19917. （原始内容存档于2020-06-07）（英语）.
[4]
Osterholm, Michael T.; Kelley, Nicholas S.; Sommer, Alfred; Belongia, Edward A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2012-01-01, 12 (1) [2022-11-02]. ISSN 1473-3099. PMID 22032844. doi:10.1016/S1473-3099(11)70295-X. （原始内容存档于2018-09-14）（英语）.
[5]
Jefferson, Tom; Di Pietrantonj, Carlo; Al-Ansary, Lubna A.; Ferroni, Eliana; Thorning, Sarah; Thomas, Roger E. Vaccines for preventing influenza in the elderly. The Cochrane Database of Systematic Reviews. 2010-02-17, (2) [2022-11-02]. ISSN 1469-493X. PMID 20166072. doi:10.1002/14651858.CD004876.pub3. （原始内容存档于2022-11-23）.
[6]
Demicheli, Vittorio; Jefferson, Tom; Al-Ansary, Lubna A.; Ferroni, Eliana; Rivetti, Alessandro; Di Pietrantonj, Carlo. Vaccines for preventing influenza in healthy adults. The Cochrane Database of Systematic Reviews. 2014-03-13, (3) [2022-11-02]. ISSN 1469-493X. PMID 24623315. doi:10.1002/14651858.CD001269.pub5. （原始内容存档于2023-03-15）.
[7]
Who Should Get Vaccinated Against Influenza. U.S. Centers for Disease Control and Prevention. 2015-11-04 [2015-12-08]. （原始内容存档于2014-01-22）.
[8]
Sook-San Wong and Richard J. Webby. Traditional and New Influenza Vaccines. Clin Microbiol Rev. 2013 Jul; 26(3): 476–492. [2023-03-14]. doi:10.1128/CMR.00097-12. （原始内容存档于2023-03-14）.
[9]
Comparison of live attenuated influenza vaccine (LAIV), inactivated influenza vaccine (IIV), and recombinant influenza vaccine (RIV) for prevention of seasonal influenza, United States formulations for persons younger than 65 years. [2022-11-03]. （原始内容存档于2022-11-03）.
[10]
Brunton, Laurence L; Hilal-Dandan, Randa; Knollmann, Björn C. Goodman Gilmans The Pharmacological Basis of Therapeutics. The United States: McGraw-Hill Education. 2018: 666–667. ISBN 978-1-25-958474-9.
[11]
Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLOS Medicine. April 2010, 7 (4): e1000258. PMC 2850386 . PMID 20386731. doi:10.1371/journal.pmed.1000258.
[12]
Tapia, R.; Torremorell, M.; Culhane, M.; et al. Antigenic characterization of novel H1 influenza A viruses in swine. [2023-03-14]. （原始内容存档于2023-03-16）.
[13]
Recommendations for Influenza Vaccine Composition Northern hemisphere November 1998-April 1999. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[14]
Recommendations for Influenza Vaccine Composition Northern hemisphere: November 1999 to April 2000. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[15]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2000-2001. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[16]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2001-2002. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[17]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2002-2003. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[18]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2003-2004. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[19]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2004-2005. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[20]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2005-2006. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[21]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2006-2007. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[22]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2007-2008. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[23]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2008-2009. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[24]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2009-2010. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.
[25]
Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于28 October 2013）.
[26]
不属于1～7，为1～7系的祖型
[27]
Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于9 October 2011）.
[28]
Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于27 February 2012）.
[29]
Standardization of terminology of the pandemic A(H1N1) 2009 virus (PDF). World Health Organization (WHO). [14 June 2012]. （原始内容存档 (PDF)于2022-03-08）.
[30]
Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. World Health Organization (WHO). [22 February 2013]. （原始内容存档于1 March 2013）.
[31]
Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. World Health Organization (WHO). [20 February 2014]. （原始内容存档于25 February 2014）.
[32]
Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. World Health Organization (WHO). [2 March 2015]. （原始内容存档于6 March 2015）.
[33]
Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. World Health Organization (WHO). [19 May 2016]. （原始内容存档于4 March 2016）.
[34]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Weekly Epidemiological Record. March 2016, 91 (10): 121–32. PMID 26971356. hdl:10665/254302.
[35]
Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. World Health Organization (WHO). [16 March 2017]. （原始内容存档于7 March 2017）.
[36]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Weekly Epidemiological Record. March 2017, 92 (11): 117–28. PMID 28303704. hdl:10665/254758.
[37]
WHO switches H1N1 in Southern Hemisphere flu vaccine. University of Minnesota - Center for Infectious Disease Research and Policy (CIDRAP). 29 September 2016 [12 September 2017]. （原始内容存档于2017-09-12）. A/Michigan/45/2015 replaces the longstanding A/California/7/2009 and is recommended to improve protection against two subclades that have emerged over the past season.
[38]
Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. World Health Organization (WHO). [22 February 2018]. （原始内容存档于26 February 2018）.
[39]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Weekly Epidemiological Record. March 2018, 93 (12): 133–41. PMID 29569429. hdl:10665/272270.
[40]
Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. World Health Organization (WHO). [22 March 2019]. （原始内容存档于29 March 2022）.
[41]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Weekly Epidemiological Record. March 2019, 94 (12): 141–50. hdl:10665/311441.
[42]
World Health Organization. Addendum to the Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Weekly Epidemiological Record. March 2019, 94 (13): 166–8. hdl:10665/311555.
[43]
Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. World Health Organization (WHO). [28 February 2020]. （原始内容存档于12 March 2020）.
[44]
Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season. World Health Organization (WHO). [26 February 2021]. （原始内容存档于26 February 2021）.
[45]
Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. World Health Organization (WHO). 25 February 2022 [29 March 2022]. （原始内容存档于29 March 2022）.
[46]
Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. World Health Organization (WHO). 24 February 2023 [17 March 2023]. （原始内容存档于8 March 2023）.
[47]
Compans, Richard W.; Orenstein, Walter A. Vaccines for Pandemic Influenza. Springer Science & Business Media. 2009-09-18: 49 [2016-03-12]. ISBN 978-3-540-92165-3. （原始内容存档于2022-10-24）（英语）.
[48]
Nunnally, Brian K.; Turula, Vincent E.; Sitrin, Robert D. Vaccine Analysis: Strategies, Principles, and Control. Springer. 2014-11-27: 61 [2016-03-12]. ISBN 978-3-662-45024-6. （原始内容存档于2022-10-24）（英语）.
[49]
19th WHO Model List of Essential Medicines (April 2015) (PDF). WHO. April 2015 [2015-05-10]. （原始内容存档 (PDF)于2015-05-13）.
[50]
Vaccine, influenza. International Drug Price Indicator Guide. [2015-12-06].^{[失效連結]}
[51]
Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 314. ISBN 9781284057560.

[Swine-13] [N 1]
早期针对人类流感病毒进行详细谱系，仅存在最接近的猪H1流感病毒的HA蛋白谱系，一些最接近人H1N1流感病毒的猪H1流感病毒甚至属于H1N2型。

[eitherStrain-16] [N 2]
The recommendation was for either the B Victoria or the B Yamagata strain.

[pdm09-31] [N 3]
(H1N1)pdm09 is newer nomenclature for the 2009 pandemic H1N1 virus, not a different strain.

[texas-34] [N 4]
It is recommended that A/Texas/50/2012 is used as the A(H3N2) vaccine component because of antigenic changes in earlier A/Victoria/361/2011-like vaccine viruses (such as IVR-165) resulting from adaptation to propagation in eggs.

[Victoria_361_2011-36] [N 5]
A/Texas/50/2012 is an A(H3N2) virus that following adaptation to growth in eggs has maintained antigenic properties similar to the majority of recently circulating cell-propagated A(H3N2) viruses including A/Victoria/361/2011

[AHFS2015-1] [1]
Influenza Virus Vaccine Inactivated. The American Society of Health-System Pharmacists. [2015-01-08]. （原始内容存档于2014-12-25）.

[WHO2012-2] [2]
Vaccines against influenza WHO position paper – November 2012. Releve Epidemiologique Hebdomadaire. 2012-11-23, 87 (47) [2022-11-02]. ISSN 0049-8114. PMID 23210147. （原始内容存档于2022-11-02）.

[Man2012-3] [3]
Manzoli, Lamberto; Ioannidis, John P.A.; Flacco, Maria Elena; De Vito, Corrado; Villari, Paolo. Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: A critical review and re-analysis of 15 meta-analyses. Human Vaccines & Immunotherapeutics. 2012-07, 8 (7) [2022-11-02]. ISSN 2164-5515. PMC 3495721 . PMID 22777099. doi:10.4161/hv.19917. （原始内容存档于2020-06-07）（英语）.

[Ost2012-4] [4]
Osterholm, Michael T.; Kelley, Nicholas S.; Sommer, Alfred; Belongia, Edward A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2012-01-01, 12 (1) [2022-11-02]. ISSN 1473-3099. PMID 22032844. doi:10.1016/S1473-3099(11)70295-X. （原始内容存档于2018-09-14）（英语）.

[5] [5]
Jefferson, Tom; Di Pietrantonj, Carlo; Al-Ansary, Lubna A.; Ferroni, Eliana; Thorning, Sarah; Thomas, Roger E. Vaccines for preventing influenza in the elderly. The Cochrane Database of Systematic Reviews. 2010-02-17, (2) [2022-11-02]. ISSN 1469-493X. PMID 20166072. doi:10.1002/14651858.CD004876.pub3. （原始内容存档于2022-11-23）.

[6] [6]
Demicheli, Vittorio; Jefferson, Tom; Al-Ansary, Lubna A.; Ferroni, Eliana; Rivetti, Alessandro; Di Pietrantonj, Carlo. Vaccines for preventing influenza in healthy adults. The Cochrane Database of Systematic Reviews. 2014-03-13, (3) [2022-11-02]. ISSN 1469-493X. PMID 24623315. doi:10.1002/14651858.CD001269.pub5. （原始内容存档于2023-03-15）.

[WhoShouldVax-7] [7]
Who Should Get Vaccinated Against Influenza. U.S. Centers for Disease Control and Prevention. 2015-11-04 [2015-12-08]. （原始内容存档于2014-01-22）.

[FlushotClassif-8] [8]
Sook-San Wong and Richard J. Webby. Traditional and New Influenza Vaccines. Clin Microbiol Rev. 2013 Jul; 26(3): 476–492. [2023-03-14]. doi:10.1128/CMR.00097-12. （原始内容存档于2023-03-14）.

[9] [9]
Comparison of live attenuated influenza vaccine (LAIV), inactivated influenza vaccine (IIV), and recombinant influenza vaccine (RIV) for prevention of seasonal influenza, United States formulations for persons younger than 65 years. [2022-11-03]. （原始内容存档于2022-11-03）.

[:0-10] [10]
Brunton, Laurence L; Hilal-Dandan, Randa; Knollmann, Björn C. Goodman Gilmans The Pharmacological Basis of Therapeutics. The United States: McGraw-Hill Education. 2018: 666–667. ISBN 978-1-25-958474-9.

[Skowronski_2010-11] [11]
Skowronski DM, De Serres G, Crowcroft NS, Janjua NZ, Boulianne N, Hottes TS, et al. Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLOS Medicine. April 2010, 7 (4): e1000258. PMC 2850386 . PMID 20386731. doi:10.1371/journal.pmed.1000258.

[SwineH1Clade-12] [12]
Tapia, R.; Torremorell, M.; Culhane, M.; et al. Antigenic characterization of novel H1 influenza A viruses in swine. [2023-03-14]. （原始内容存档于2023-03-16）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere_November_1998-April_1999-14] [13]
Recommendations for Influenza Vaccine Composition Northern hemisphere November 1998-April 1999. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_November_1999_to_April_2000-15] [14]
Recommendations for Influenza Vaccine Composition Northern hemisphere: November 1999 to April 2000. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2000-2001-17] [15]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2000-2001. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2001-2002-18] [16]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2001-2002. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2002-2003-19] [17]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2002-2003. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2003-2004-20] [18]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2003-2004. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2004-2005-21] [19]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2004-2005. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2005-2006-22] [20]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2005-2006. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2006-2007-23] [21]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2006-2007. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2007-2008-24] [22]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2007-2008. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2008-2009-25] [23]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2008-2009. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[Recommendations_for_Influenza_Vaccine_Composition_Northern_hemisphere:_2009-2010-26] [24]
Recommendations for Influenza Vaccine Composition Northern hemisphere: 2009-2010. World Health Organization (WHO). [14 June 2012]. （原始内容存档于29 April 2013）.

[2010-2011_northern_WHO-27] [25]
Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于28 October 2013）.

[28] [26]
不属于1～7，为1～7系的祖型

[2011-2012_northern_WHO-29] [27]
Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于9 October 2011）.

[2012-2013_northern_WHO-30] [28]
Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. World Health Organization (WHO). [14 June 2012]. （原始内容存档于27 February 2012）.

[Standardization_of_terminology_of_the_pandemic_A(H1N1)_2009_virus-32] [29]
Standardization of terminology of the pandemic A(H1N1) 2009 virus (PDF). World Health Organization (WHO). [14 June 2012]. （原始内容存档 (PDF)于2022-03-08）.

[2013-2014_northern_WHO-33] [30]
Recommended composition of influenza virus vaccines for use in the 2013-2014 northern hemisphere influenza season. World Health Organization (WHO). [22 February 2013]. （原始内容存档于1 March 2013）.

[2014-2015_northern_WHO-35] [31]
Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. World Health Organization (WHO). [20 February 2014]. （原始内容存档于25 February 2014）.

[2015-2016_northern_WHO-37] [32]
Recommended composition of influenza virus vaccines for use in the 2015-2016 northern hemisphere influenza season. World Health Organization (WHO). [2 March 2015]. （原始内容存档于6 March 2015）.

[2016-2017_northern_WHO-38] [33]
Recommended composition of influenza virus vaccines for use in the 2016-2017 northern hemisphere influenza season. World Health Organization (WHO). [19 May 2016]. （原始内容存档于4 March 2016）.

[39] [34]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season. Weekly Epidemiological Record. March 2016, 91 (10): 121–32. PMID 26971356. hdl:10665/254302.

[2017-2018_northern_WHO-40] [35]
Recommended composition of influenza virus vaccines for use in the 2017-2018 northern hemisphere influenza season. World Health Organization (WHO). [16 March 2017]. （原始内容存档于7 March 2017）.

[41] [36]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2017–2018 northern hemisphere influenza season. Weekly Epidemiological Record. March 2017, 92 (11): 117–28. PMID 28303704. hdl:10665/254758.

[michig-42] [37]
WHO switches H1N1 in Southern Hemisphere flu vaccine. University of Minnesota - Center for Infectious Disease Research and Policy (CIDRAP). 29 September 2016 [12 September 2017]. （原始内容存档于2017-09-12）. A/Michigan/45/2015 replaces the longstanding A/California/7/2009 and is recommended to improve protection against two subclades that have emerged over the past season.

[2018-2019_northern_WHO-43] [38]
Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season. World Health Organization (WHO). [22 February 2018]. （原始内容存档于26 February 2018）.

[44] [39]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2018–2019 northern hemisphere influenza season. Weekly Epidemiological Record. March 2018, 93 (12): 133–41. PMID 29569429. hdl:10665/272270.

[2019-2020_northern_WHO-45] [40]
Recommended composition of influenza virus vaccines for use in the 2019-2020 northern hemisphere influenza season. World Health Organization (WHO). [22 March 2019]. （原始内容存档于29 March 2022）.

[46] [41]
World Health Organization. Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Weekly Epidemiological Record. March 2019, 94 (12): 141–50. hdl:10665/311441.

[Addendum_to_the_Recommended_composition_of_influenza_virus_vaccines_for_use_in_the_2019–2020_northern_hemisphere_influenza_season-47] [42]
World Health Organization. Addendum to the Recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season. Weekly Epidemiological Record. March 2019, 94 (13): 166–8. hdl:10665/311555.

[2020-2021_northern_WHO-48] [43]
Recommended composition of influenza virus vaccines for use in the 2020-2021 northern hemisphere influenza season. World Health Organization (WHO). [28 February 2020]. （原始内容存档于12 March 2020）.

[2021-2022_northern_WHO-49] [44]
Recommended composition of influenza virus vaccines for use in the 2021-2022 northern hemisphere influenza season. World Health Organization (WHO). [26 February 2021]. （原始内容存档于26 February 2021）.

[2022-2023_northern_WHO-50] [45]
Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. World Health Organization (WHO). 25 February 2022 [29 March 2022]. （原始内容存档于29 March 2022）.

[2023-2024_northern_WHO-51] [46]
Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. World Health Organization (WHO). 24 February 2023 [17 March 2023]. （原始内容存档于8 March 2023）.

[52] [47]
Compans, Richard W.; Orenstein, Walter A. Vaccines for Pandemic Influenza. Springer Science & Business Media. 2009-09-18: 49 [2016-03-12]. ISBN 978-3-540-92165-3. （原始内容存档于2022-10-24）（英语）.

[53] [48]
Nunnally, Brian K.; Turula, Vincent E.; Sitrin, Robert D. Vaccine Analysis: Strategies, Principles, and Control. Springer. 2014-11-27: 61 [2016-03-12]. ISBN 978-3-662-45024-6. （原始内容存档于2022-10-24）（英语）.

[54] [49]
19th WHO Model List of Essential Medicines (April 2015) (PDF). WHO. April 2015 [2015-05-10]. （原始内容存档 (PDF)于2015-05-13）.

[55] [50]
Vaccine, influenza. International Drug Price Indicator Guide. [2015-12-06].^{[失效連結]}

[Ric2015-56] [51]
Hamilton, Richart. Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. 2015: 314. ISBN 9781284057560.

[2]

[3]

[4]

[5]

[6]

[7]

[1]

[8]

[9]

[10]

[11]

[12]

[note 1]

[13]

[14]

[note 2]

[15]

[16]

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

[note 3]

[29]

[30]

[note 4]

[31]

[note 5]

[32]

[33]

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

[49]

[50]

[51]